The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning ...

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...

A study shows reduced-dose apixaban effectively prevents recurrent blood clots in cancer patients, lowering bleeding risks ...

Just as effective as the high dose, low-dose apixaban prevents long-term recurrent venous thromboembolism in patients with ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least ...

Results show noninferiority to a full dose in preventing a recurrence of blood clots and an advantage when it comes to ...

CHICAGO -- For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of ...

or 10 mg (5 mg twice daily; the full-dose group) of apixaban for an additional 12 months. Neither patients nor their doctors knew which dose patients were receiving until the end of the trial.

Researchers randomly assigned 1,766 patients to receive oral apixaban twice daily at a reduced dose of 2.5 mg or a full dose of 5 mg for 12 months. All participants had active cancer and had completed ...